Tocqueville Asset Management L.P. Sells 76,936 Shares of CVS Health Corporation $CVS

Tocqueville Asset Management L.P. lessened its stake in CVS Health Corporation (NYSE:CVS) by 20.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 307,161 shares of the pharmacy operator’s stock after selling 76,936 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in CVS Health were worth $23,157,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of CVS Health by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after acquiring an additional 2,063,737 shares during the last quarter. Capital World Investors increased its stake in CVS Health by 2.1% in the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after acquiring an additional 1,419,575 shares during the last quarter. State Street Corp raised its position in CVS Health by 1.4% during the second quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after purchasing an additional 800,414 shares in the last quarter. Geode Capital Management LLC lifted its stake in CVS Health by 2.4% during the second quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock worth $1,966,083,000 after purchasing an additional 675,824 shares during the last quarter. Finally, Capital International Investors boosted its holdings in shares of CVS Health by 1.1% in the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after purchasing an additional 302,499 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 0.9%

CVS Health stock traded up $0.71 during trading hours on Friday, reaching $76.78. The company had a trading volume of 876,434 shares, compared to its average volume of 9,014,825. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The company has a 50-day moving average price of $78.25 and a 200 day moving average price of $77.71. The firm has a market cap of $97.68 billion, a price-to-earnings ratio of 55.58, a P/E/G ratio of 0.79 and a beta of 0.49.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same quarter in the prior year, the firm posted $1.19 earnings per share. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a yield of 3.5%. CVS Health’s dividend payout ratio is presently 192.75%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” and raised its price target (cited in market coverage), signaling analyst confidence that could support further upside. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced an AI-powered health platform rollout, pointing to digital/service-led revenue expansion and potential margin benefits over time if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause-accredited, expanding clinical services in retail/clinic channels — a small but constructive example of diversifying care offerings. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are updating valuations: one fair-value update nudged CVS’s estimate slightly higher (~$96.38), reflecting optimism on Medicare Advantage but continued debate on managed-care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Comparison pieces and retirement-portfolio coverage (CVS vs. Cigna) highlight CVS’s diversified model (retail, PBM, insurance) — useful context for longer-term investors but not an immediate catalyst. CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?
• Negative Sentiment: Aetna, a CVS unit, agreed to pay $117.7M to resolve DOJ False Claims Act allegations over Medicare Advantage coding — a meaningful compliance cost and a reminder of regulatory/legal risk for managed-care operations. CVS Health’s Aetna to Pay $117.7 Million to Resolve False Claims Act Allegations
• Negative Sentiment: CVS warned it may close 100+ Tennessee pharmacies over proposed PBM legislation — a potential near-term hit to retail revenues, local access and political/regulatory uncertainty in pharmacy operations. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

Analyst Ratings Changes

A number of brokerages recently weighed in on CVS. Wells Fargo & Company decreased their price objective on CVS Health from $103.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 13th. Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a research note on Thursday, March 5th. Morgan Stanley increased their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. TD Cowen boosted their price objective on shares of CVS Health from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Twenty investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average price target of $95.05.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.